ISB News

Melding ISB and FHCRC Brain Power for Cancer Research

ISB's Ilya Shmulevich describes his lab's work in The Cancer Genome Atlas project and how ISB and FHCRC could collaborate.

(Photo above: ISB’s Dr. Ilya Shmulevich describes his lab’s work in The Cancer Genome Atlas project and how ISB and FHCRC could collaborate.)

Big health challenges require big science. Cancers are prime examples of overwhelmingly complex diseases that need the power of a cross-disciplinary, systems biology approach to decipher the underlying dysfunctional gene networks in order to find ways to prevent and manage the diseases and develop more effective therapies.

ISB's Dr. Nathan Price, left, chats with FHCRC's Dr. David Hockenbery and Dr. Eric Holland during a meeting held at Institute for Systems Biology to discuss potential collaborations on cancer research.

ISB’s Dr. Nathan Price, left, chats with FHCRC’s Dr. David Hockenbery and Dr. Eric Holland during a meeting held at Institute for Systems Biology to discuss potential collaborations on cancer research.

On May 6 at Institute for Systems Biology, researchers from ISB and Fred Hutchinson Cancer Research Center – specifically the Human Biology Division – gathered for a meeting of great minds to identify potential areas for collaboration. It was an intimate showcase for commingling ISB’s pioneering systems approach with the depth of cancer biology knowledge from FHCRC.

 

“We are laying the foundation for a strategic partnership that combines the best of both institutions to attack cancers with systems biology.”

Dr. Nitin Baliga, Senior Vice President and Director of ISB, and project coordinator Dr. Julie Bletz, worked with Dr. Eric Holland, Senior Vice President and Director of the Human Biology Division at FHCRC, to organize the day-long meeting. After introductions, 15 ISB and FHCRC researchers alternated to present their areas of expertise, research challenges, what strengths his/her group could bring to the table and what complementary collaboration the group seeks. The 15 rapid-fire presentations consisted of 15-minute research summaries plus 5 minutes for questions and answers.

The day concluded with group discussions on three topics: potential partnerships and funding opportunities that can be pursued at the investigator level; types of resources both institutions can share and invest in jointly; one or two big problems that both organizations can attack collectively.

“It was a great day, with lots of interesting discussions and potential for collaboration,” said Baliga. “We are laying the foundation for a strategic partnership that combines the best of both institutions to attack cancers with systems biology.”

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.